BRIEF-Cstone Pharmaceuticals Says Sugemalimab Granted Breakthrough Therapy Designation

Reuters · 02/08/2021 01:25
BRIEF-Cstone Pharmaceuticals Says Sugemalimab Granted Breakthrough Therapy Designation

- CStone Pharmaceuticals 2616.HK:

  • ANTI-PD-L1 ANTIBODY SUGEMALIMAB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY CHINA NMPA CENTER FOR DRUG EVALUATION

Source text for Eikon: ID:nHKS5w4M4T

Further company coverage: 2616.HK


((reuters.briefs@thomsonreuters.com))